scispace - formally typeset
S

Sicheng Wang

Researcher at Second Military Medical University

Publications -  29
Citations -  474

Sicheng Wang is an academic researcher from Second Military Medical University. The author has contributed to research in topics: Medicine & Biology. The author has an hindex of 6, co-authored 9 publications receiving 169 citations.

Papers
More filters
Journal ArticleDOI

Comparison between radial head replacement and open reduction and internal fixation in clinical treatment of unstable, multi-fragmented radial head fractures.

TL;DR: Compared with open reduction and internal fixation, radial head replacement with a metal prostheses resulted in favourable joint function for the unstable, multi-fragmented fractures of the radial head.
Journal ArticleDOI

Neutrophil-erythrocyte hybrid membrane-coated hollow copper sulfide nanoparticles for targeted and photothermal/ anti-inflammatory therapy of osteoarthritis

TL;DR: In this article , a hybrid membranes-coated hollow copper sulfide nanoparticles (D-CuS@NR NPs) were fabricated for osteoarthritis (OA) treatment, which achieved the synergistic treatment of mild heating, prolonged circulation, and targeted delivery in this system.
Journal ArticleDOI

RANKL from bone marrow adipose lineage cells promotes osteoclast formation and bone loss.

TL;DR: In this paper, a conditional deletion of the receptor activator of NF-κB ligand (RANKL) from BM adipose lineage cells was shown to increase the cancellous bone mass of long bones in mice by reducing the formation of trabecular osteoclasts and inhibiting bone resorption.
Journal ArticleDOI

Rational Design of Multifunctional CuS Nanoparticle‐PEG Composite Soft Hydrogel‐Coated 3D Hard Polycaprolactone Scaffolds for Efficient Bone Regeneration

TL;DR: It is demonstrated that the Dexp‐loaded CuS‐PEG‐hydrogel can effectively modify the 3D printed PCL scaffold, which has the potential to become an advanced drug delivery vehicle in the treatment of large bone defects.
Journal ArticleDOI

Triptolide prevents bone loss via suppressing osteoclastogenesis through inhibiting PI3K-AKT-NFATc1 pathway.

TL;DR: The new effect of anti‐cancer drug triptolide was demonstrated to be anti‐osteoclastogenesis, and triptoide might be a promising therapy for bone loss caused by tumour.